Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 6 | 7 |
| List of Tables | 9 | 2 |
| List of Figures | 11 | 2 |
| Global Ophthalmology Therapeutics Market - Introduction | 13 | 1 |
| Overview | 13 | 1 |
| Global Ophthalmology Therapeutics Market - Market Overview | 14 | 6 |
| Introduction | 14 | 1 |
| Revenue | 15 | 2 |
| Annual Cost of Treatment | 17 | 1 |
| Treatment Usage Pattern | 18 | 1 |
| Branded and Generic Market Share | 19 | 1 |
| Global Ophthalmology Therapeutics Market - Geographical Landscape | 20 | 13 |
| Geographical Break-up | 20 | 1 |
| The US | 20 | 1 |
| Revenue | 20 | 1 |
| Annual Cost of Treatment | 21 | 1 |
| Treatment Usage Pattern | 22 | 2 |
| Top Five Countries in Europe | 24 | 1 |
| Revenue | 24 | 2 |
| Annual Cost of Treatment | 26 | 1 |
| Treatment Usage Pattern | 27 | 2 |
| Japan | 29 | 1 |
| Revenue | 29 | 1 |
| Annual Cost of Treatment | 30 | 1 |
| Treatment Usage Pattern | 31 | 2 |
| Global Ophthalmology Therapeutics Market - Therapeutic Landscape | 33 | 51 |
| Glaucoma Therapeutics Market | 33 | 1 |
| Introduction | 33 | 3 |
| Prostaglandin-based Therapies are currently Considered Favored First-line Treatments | 36 | 1 |
| Pfizer s Xalatan/Xalcom Revenue Hit by Entry of Generics | 36 | 1 |
| Lumigan and Travatan Approaching Patent Expiry Market Set to Dip Further | 36 | 1 |
| Europe Significantly More Lenient in Approving Combination Products compared to the US | 37 | 1 |
| Revenue | 38 | 2 |
| Annual Cost of Treatment | 40 | 1 |
| Treatment Usage Pattern | 41 | 2 |
| Treatment Flow Algorithm | 43 | 1 |
| Branded and Generic Market Share | 44 | 1 |
| Drivers for the Glaucoma Therapeutics Market | 45 | 1 |
| Improved Diagnosis of the Disease | 45 | 1 |
| Restraints for Glaucoma Therapeutics Market | 45 | 1 |
| Lower Awareness and Treatment-seeking Rates | 45 | 1 |
| The Patent Expiry of Major Glaucoma Drugs such as Lumigan and Alphagan will Result in Negative Growth | 45 | 1 |
| Geographical Segmentation | 46 | 1 |
| Allergic Conjunctivitis Therapeutics Market | 47 | 1 |
| Introduction | 47 | 1 |
| Increasing Awareness Driving the Market for Allergic Conjunctivitis | 48 | 1 |
| Revenue | 49 | 1 |
| Annual Cost of Treatment | 50 | 1 |
| Treatment Usage Pattern | 51 | 2 |
| Treatment Flow Algorithm | 53 | 1 |
| Branded and Generic Market Share | 54 | 1 |
| Geographical Segmentation | 55 | 1 |
| Wet Age Macular Degeneration Therapeutics Market | 56 | 1 |
| Introduction | 56 | 1 |
| First Wave of AMD Treatment Used Lasers | 57 | 1 |
| Visudyne Used in Photodynamic Therapy Destroys Blood Vessels | 57 | 1 |
| Changing Paradigm of Wet AMD Treatment | 57 | 1 |
| Anti-angiogenesis Treatments Dominate the AMD Market | 57 | 1 |
| Eylea by Regeneron Made a Strong Start Commercially, Backed by Clinical Results | 58 | 1 |
| Combination Therapy of Fovista and Lucentis Demonstrated Improvement in Vision in Phase II Trials | 58 | 1 |
| Revenue | 59 | 2 |
| Annual Cost of Treatment | 61 | 1 |
| Treatment Usage Pattern | 62 | 2 |
| Treatment Flow Algorithm | 64 | 1 |
| Branded and Generic Market Share | 65 | 1 |
| Drivers for Wet Age-related Macular Degeneration Therapeutics Market | 65 | 1 |
| Elderly Population to Drive wet AMD Market | 65 | 1 |
| Improvements in Diagnostic Tools will Increase the Diagnosed Population | 65 | 1 |
| Restraints for Wet Age-Related Macular Degeneration Therapeutics Market | 66 | 1 |
| Poor Treatment-seeking Rates for Wet AMD will Result in a Very Small Potential Customer Segment | 66 | 1 |
| Off-label Use of Avastin Impact Annual Cost of Therapy | 66 | 1 |
| Geographical Segmentation | 66 | 2 |
| Diabetic Macular Edema Therapeutics Market | 68 | 1 |
| Introduction | 68 | 1 |
| Marketed by Novartis, Lucentis Gained approval for DME in Europe | 68 | 1 |
| Off-label Usage of Intravitreal Corticosteroids and Investigational New Drugs also Popular | 69 | 1 |
| Alimera s Iluvien Approved in Several European Countries but Rejected in the US | 69 | 1 |
| Avastin s Use in DME Relatively Tempered due to Adverse Effects | 69 | 1 |
| Ozurdex Expected to be Launched in the US Soon | 69 | 1 |
| Revenue | 70 | 1 |
| Annual Cost of Treatment | 71 | 1 |
| Treatment Usage Pattern | 72 | 2 |
| Treatment Flow Algorithm | 74 | 1 |
| Drivers for Diabetic Macular Edema Therapeutics Market | 74 | 1 |
| Increasing Prevalence of Conditions Such as Diabetes will Drive the Market | 74 | 1 |
| Improved Awareness will Drive Volumes | 74 | 1 |
| Restraints for Diabetic Macular Edema Therapeutics Market | 75 | 1 |
| Availability of Alternative Options such as Laser Treatment | 75 | 1 |
| Geographical Segmentation | 75 | 1 |
| Dry Eye Syndrome, Therapeutics Market | 76 | 1 |
| Introduction | 76 | 1 |
| Varied Treatment Options for DES | 76 | 1 |
| Rebamipide is in Phase II Trials in the US | 76 | 1 |
| Androgen Tear by Allergan may Provide a New Treatment Option | 76 | 1 |
| Revenue | 77 | 1 |
| Annual Cost of Treatment | 78 | 1 |
| Treatment Usage Pattern | 79 | 1 |
| Treatment Flow Algorithm | 80 | 1 |
| Branded and Generic Market Share | 81 | 1 |
| Drivers for Dry Eye Syndrome Therapeutics Market | 81 | 1 |
| Increase in Prevalence | 81 | 1 |
| Restraints for Dry Eye Syndrome Therapeutics Market | 81 | 1 |
| Low Treatment-seeking Rate | 81 | 1 |
| Inadequate Treatment Options | 81 | 1 |
| Geographical Segmentation | 82 | 2 |
| Global Ophthalmology Therapeutics Market - APAC | 84 | 5 |
| India | 84 | 1 |
| Overview | 84 | 1 |
| Key Trends | 84 | 1 |
| Key Strategies | 85 | 1 |
| China | 86 | 1 |
| Overview | 86 | 1 |
| Key Trends | 86 | 1 |
| Key Strategies | 87 | 1 |
| Australia | 88 | 1 |
| Overview | 88 | 1 |
| Pricing and Reimbursement | 88 | 1 |
| Global Ophthalmology Therapeutics Market - Profiles of Promising Pipeline Products | 89 | 3 |
| Iluvien (fluocinolone acetonide) | 89 | 1 |
| Overview | 89 | 1 |
| Efficacy | 89 | 1 |
| Safety | 89 | 1 |
| Clinical Study Details | 89 | 1 |
| Rebamipide (OPC-12759E) | 90 | 1 |
| Overview | 90 | 1 |
| Clinical Details | 90 | 1 |
| Remura (bromfenac) | 90 | 1 |
| Overview | 90 | 1 |
| Clinical details | 90 | 1 |
| Ozurdex (dexamethasone) | 90 | 1 |
| Overview | 90 | 1 |
| Clinical Details | 90 | 1 |
| ISTA -Ecabet Sodium | 91 | 1 |
| Overview | 91 | 1 |
| Allergan s Androgen Tear | 91 | 1 |
| Overview | 91 | 1 |
| Global Ophthalmology Therapeutics Market - Competitive Landscape | 92 | 5 |
| Allergan, Inc. | 92 | 1 |
| Business Overview | 92 | 1 |
| SWOT | 92 | 1 |
| Merck &Co Inc | 93 | 1 |
| Introduction | 93 | 1 |
| SWOT | 93 | 1 |
| Novartis AG | 94 | 1 |
| Introduction | 94 | 1 |
| SWOT | 95 | 1 |
| Pfizer | 95 | 1 |
| Business Description | 95 | 1 |
| SWOT | 96 | 1 |
| Roche | 96 | 1 |
| Introduction | 96 | 1 |
| SWOT | 96 | 1 |
| Global Ophthalmology Therapeutics Market - Strategic Consolidations | 97 | 6 |
| Mergers and Acquisitions | 97 | 1 |
| Introduction | 97 | 1 |
| Key Mergers and Acquisitions Deals | 97 | 1 |
| Bosch + Lomb Acquires Ista Pharmaceuticals | 97 | 1 |
| Merck s Acquisition of Inspire Pharmaceuticals | 97 | 1 |
| Novartis Completes Acquisition of Remaining 23% Stake in Alcon | 97 | 1 |
| Segmentation by Geography | 98 | 1 |
| Segmentation by Deal Value | 99 | 1 |
| Co-development Deals | 100 | 1 |
| Major Co-development Deals | 100 | 1 |
| SurModics Enters into License and Development Agreement with F. Hoffmann-La Roche and Genentech | 100 | 1 |
| Lpath Enters into Licensing Agreement with Pfizer | 100 | 1 |
| Segmentation by Geography | 100 | 1 |
| Licensing Deals | 101 | 1 |
| Major Licensing Deals | 101 | 1 |
| Acucela Enters into Co-development Agreement with Otsuka Pharmaceutical for OPA-6566 | 101 | 1 |
| AstraZeneca Enters into Co-development Agreement with University College London | 101 | 1 |
| Segmentation by Geography | 101 | 1 |
| Segmentation by Value | 102 | 1 |
| Global Ophthalmology Therapeutics Market - Appendix | 103 | 9 |
| Market Definitions | 103 | 1 |
| Abbreviations | 103 | 2 |
| Bibliography | 105 | 1 |
| Research Methodology | 106 | 2 |
| Coverage | 106 | 1 |
| Secondary Research | 106 | 1 |
| Primary Research | 107 | 1 |
| Therapeutic Landscape | 107 | 4 |
| Epidemiology-based Forecasting | 108 | 2 |
| Market Size by Geography | 110 | 1 |
| Geographical Landscape | 111 | 1 |
| Pipeline Analysis | 111 | 1 |
| Competitive Landscape | 111 | 1 |
| Expert Panel Validation | 111 | 1 |
| Contact Us | 111 | 1 |
| Disclaimer | 111 | 1 |